By Nolan Miles
P3 Kentucky Staff Writer
Over the next five years, $215 million will be used to fund a new public-private partnership designed to research immunotherapy treatment in support of the Cancer Moonshot initiative. The initiative is led by the National Institutes of Health.
Known as the Partnership for Accelerating Cancer Therapies, or PACT, the partnership brings together the the NIH and 11 biopharmaceutical vendors. The private sector will contribute more than $55 million to the effort over five years.
PACT will fund research to identify, develop and validate how immunotherapies work. The Cancer Moonshot initiative has a mission to achieve a decade’s worth of progress against cancer in the next five years.
“We support PACT because collaboration is an important step that can lead to new breakthroughs and possibly even a chance for cure,” said Dr. Edith Perez, vice president and head of BioOncology Medical Affairs at Genentech, as well as director of the Mayo Clinic Breast Cancer Translational Genomics Program. “When industry, academia and government work together to share scientific knowledge and new technologies, we have a chance to make significant strides in the fight against cancer and to ultimately help more people.”
For the full story, click here.